NCT04414969招募中2 期
Anti-PD-1 Antibody, Peg-Asparaginase, Chidamide Combined With Radiotherapy for the First-line Treatment of Patients With Stage I/II Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (ENKTL): An Open-label, Multicenter, Phase II Trial
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 35
- 试验地点
- 1
- 主要终点
- Objective response rate (ORR)
研究概览
简要总结
This prospective pilot study to evaluate the efficacy and safety of the anti-PD-1 antibody combine with Peg-asparaginase and Chidamide regimen for stage IE and IIE ENKTL.
详细描述
Extranodal natural killer/T-cell lymphoma (ENKTL) is an aggressive subtype of non-Hodgkin's lymphoma and shows extremely poor survival. Several retrospective studies and randomized prospective phase 2 studies have shown that Peg-aspargase based chemotherapy regimens achieved a promising efficacy in the first line treatment of ENKTL. However, about one third of patients will relapse or become refractory after Peg-aspargase-based chemotherapy followed by radiotherapy, and some patients cannot tolerate the toxicities caused by chemotherapy. Anti-PD-1/PD-L1 antibodies and Chidamide are active drugs for the treatment of relapsed/refractory ENKTL. However, there is no prospective study to evaluate the efficacy and safety of anti-PD-1 antibody combine with Peg-asparaginase and Chidamide in the newly diagnosed early stage ENKTL. This prospective pilot study to evaluate the efficacy and safety of the anti-PD-1 antibody combine with Peg-asparaginase and Chidamide regimen for stage IE and IIE ENKTL.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Pathologically confirmed, previously untreated ENKTL with stage I/II (for stage I, the patients should have one or more of the following risk factors: ①Extensive local invasion and or bone destruction: invasion of the inner orbital wall or bottom wall, orbital apex, orbital contents, maxillary sinus, sphenoid sinus, frontal sinus or ethmoid sinus invasion, hard palate, ethmoid plate, nasopharynx, slope bone is invaded. ②Skin invasion: nose and or cheek skin invasion; ③Waldeyer's ring invasion; ④LDH>upper limit of normal; ⑤EBV-DNA > upper limit of normal; ⑥B symptoms);
- •Age range from 18 to 75 years;
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0-2;
- •At least one evaluable or measurable lesion complying with Lugano 2014 Standard (evaluable lesion: the examination show increased uptake of lymph nodes or extranodal areas (higher than that of the liver) by 18F-Fluorodeoxyglucose/Positron Emission Tomography (18FDG/PET) and the PET and/or Computed Tomography (CT) features coincide with lymphoma characteristics; measurable lesion: nodal lesions were longer than 15 mm or extranodal lesions were longer than 10 mm, and accompanied by increased 18FDG uptake). Increased liver or spleen diffuse 18FDG uptake without measurable lesions should be excluded.
- •Adequate haematologic function (haemoglobin ≥90 g/l, absolute neutrophil count ≥ 1500/ml, platelets ≥ 80×10e9/l),
- •Adequate hepatic function (total serum bilirubin ≤ 1.5 times the upper limit of normal, alanine aminotransferase and aspartate aminotransferase ≤ 2.5 times the upper limit of normal),
- •Hepatitis B virus carriers should have HBV-DNA <10e4 copies and should use antiviral drugs.
- •Adequate renal function (serum creatinine ≤ 1.5 mg/dl, creatinine clearance ≥ 50 ml/min);
- •Normal coagulation function and electrocardiogram results.
- •No previous anti-cancer treatment including chemotherapy, radiotherapy, immunotherapy, biological therapy, glucocorticoids therapy for lymphoma.
- •Willingness to provide written informed consent.
排除标准
- •History of other malignancy within the past 5 years (except for basal cell carcinoma of the skin and carcinoma in situ of the cervix)
- •With clinically diagnosed hemophagocytic syndrome (HPS); or aggressive NK cell leukemia; or central nervous system invasion;
- •Previous treatments with immune checkpoint inhibitor, including nivolumab, pembrolizumab, atezolizumab, durvalumab, avelumab, ipilimumab, sintilimab, etc.
- •Previous treatments with HDAC inhibitor, including Chidamide, romidepsin, panobinostat, belinostat, etc.
- •Patients allergic of any of drug in this regimen;
- •Pregnant or lactating women
- •Participated in other clinical trials within the 4 weeks prior to enrollment;
- •History of severe hemorrhage, or any bleeding events with a severe grade of 3 or more in CTCAE 5.0 within 4 weeks prior to enrollment
- •Blood pressure unable to be controlled ideally with single antihypertensive drug therapy (Systolic blood pressure > 140 mmHg, Diastolic Blood Pressure > 90 mmHg); Clinically significant cardiovascular disease (e.g. activity) including history of CVA (within 6 months), myocardial infarction (within 6 months), unstable angina, New York Heart Association (NYHA) Grade II or greater congestive heart failure; serious cardiac arrhythmia beyond drug control or potentially affecting experimental therapy.
- •The subject is being treated with immunosuppressive agents, glucocorticoids （systemic or absorbable local using）for immunosuppression purposes (dose> 10 mg / day prednisone or other therapeutic glucocorticoids) within two weeks before enrollment the study.
- •Abnormal coagulation or bleeding tendency (It must be satisfied that INR is under normal range without anticoagulant within 14 days prior to signing informed consent); patients treated with anticoagulants or vitamin K antagonists such as warfarin, heparin or their analogues; on the premise that the international standardized ratio of prothrombin time (INR) is less than 1.5, small doses of warfarin (1 mg po, qd) or aspirin (no more than 100 mg qd) are allowed for preventive purposes.
- •Arterial or venous thromboembolic events occurred within 6 months, such as cerebrovascular accident (including transient ischemic attack), deep vein thrombosis (venous thrombosis caused by intravenous catheterization due to precancerous chemotherapy is excluded if it has been cured judged by the researchers) and pulmonary embolism.
- •Suffered major surgery within 42 days prior to enrollment;
- •Have an active autoimmune disease that requires systemic treatment within the past two years.
- •Severe or uncontrolled infections, except fever associated with lymphoma B symptoms.
- •History of psychotropic drug abuse and unable to get rid of or with mental disorders;
- •History of immunodeficiency, including HIV positive testing, or other acquired, congenital immunodeficiency disorders, or organ transplantation history;
- •Patients with concomitant diseases which could seriously endanger their own safety or could affect completion of the study according to investigators' judgment.
研究组 & 干预措施
Anti-PD-1 antibody+Peg-Asparaginase+Chidamide
Experimental
Anti-PD-1 antibody 200mg ivdrip d1; PEG-ASP 2500U/m2 im d1; Chidamide, 30mg, PO, on d1，d5，d8，d12，d15，d19; repeat every 3 weeks.
干预措施: Anti-PD-1 antibody+Peg-Asparaginase+Chidamide (Drug)
结局指标
主要结局
Objective response rate (ORR)
时间窗: 12 weeks after the initiation of the treatment
complete remission rate + partial remission rate
Complete remission rate
时间窗: 12 weeks after the initiation of the treatment
complete remission rate
次要结局
- Progression Free Survival (PFS)(Up to three years after the start of the study)
- Overall Survival (OS)(Up to three years after the start of the study)
- Safety issue(Up to one year after the end of the study)
研究者
Ya-Jun Li
Sub-Investigator
Hunan Cancer Hospital
研究点 (1)
Loading locations...
相似试验
招募中
不适用
Anti-PD-1/PD-L1 Antibodies Plus S-adenosyl-methionine Treatment in Patients With Advanced-Stage Hepatocellular CarcinomaHepatocellular CarcinomaNCT05701553Shanghai Zhongshan Hospital20
招募中
不适用
Anti-PD-1/PD-L1 Antibodies Plus Pegylated Interferon Alfa-2b Treatment in Patients With Advanced-Stage HCCHepatocellular CarcinomaNCT04943679Shanghai Zhongshan Hospital15
招募中
不适用
Anti-PD-1/PD-L1 Antibodies Plus Anti-VEGF Antibody Treatment in Patients With Advanced-Stage HCCHepatocellular CarcinomaNCT06537908Shanghai Zhongshan Hospital50
Unknown
1 期
Anti-PD-1 Antibody Combined With Anlotinib in the Treatment of Endometrial CancerEndometrial CancerNCT04157491Sun Yat-sen University23
尚未招募
2 期
Anti-PD-1 Antibody and Pegaspargase Combined With Radiotherapy in Early-Stage ENKTLExtranodal NK/T-cell Lymphoma, Nasal TypeNCT04676789Sun Yat-sen University30